| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | U54MD007595 | RCMI Center for Cancer and Health Disparities Research | 000 | 17 | NIH | 11/12/2024 | $0 |
| | 2025 | 2023 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | TL4GM118968 | BUILD at Xavier, Project Pathways II | 000 | 10 | NIH | 11/7/2024 | -$21,145 |
| | 2025 | 2023 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | RL5GM118966 | BUILD at Xavier, Project Pathways II | 000 | 10 | NIH | 11/14/2024 | $21,145 |
|
| Issue Date FY: 2024 ( Subtotal = $11,212,235 ) |
| | 2024 | 2024 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | R16GM149412 | Inhibitors of Human Factor XIIIa as New Anticoagulants | 000 | 2 | NIH | 3/5/2024 | $134,633 |
| | 2024 | 2024 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | U54MD007595 | RCMI Center for Cancer and Health Disparities Research | 009 | 17 | NIH | 9/5/2024 | $0 |
| | 2024 | 2024 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | R16GM147662 | Irreversible Estrogen Receptor Inhibitors | 000 | 3 | NIH | 6/10/2024 | $187,500 |
| | 2024 | 2024 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1098 | ORLEANS | USA | D3400006 | CENTERS OF EXCELLENCE (HBCU) | 00 | 37 | HRSA | 5/31/2024 | $2,966,653 |
| | 2024 | 2024 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | S21MD018975 | PREDICT (Precision Medicine, Education, Data Informatics and Community Translation) Institute | 000 | 2 | NIH | 6/9/2024 | $2,000,000 |
| | 2024 | 2024 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | R16GM145484 | Role of the transcriptional corepressor TLE1 in the lung adenocarcinoma aggressiveness and progression | 000 | 3 | NIH | 4/30/2024 | $145,106 |
| | 2024 | 2024 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | R16GM146801 | Regulation and Localization of Mismatch Repair Proteins | 000 | 3 | NIH | 5/15/2024 | $187,500 |
| | 2024 | 2024 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | R21AI185846 | Targeted Degradation of HIV Integrase as a Novel Treatment of Infection | 001 | 1 | NIH | 8/6/2024 | -$173,487 |
| | 2024 | 2024 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | R21AI185846 | Targeted Degradation of HIV Integrase as a Novel Treatment of Infection | 001 | 1 | NIH | 8/6/2024 | $173,487 |
| | 2024 | 2024 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | R21AI185846 | Targeted Degradation of HIV Integrase as a Novel Treatment of Infection | 000 | 1 | NIH | 8/5/2024 | $173,487 |
| | 2024 | 2024 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | R25GM137382 | Xavier University of Louisiana-Mobile Outreach for Laboratory Enrichment (XULA-MOLE) | 000 | 4 | NIH | 6/28/2024 | $263,901 |
| | 2024 | 2024 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | U54MD007595 | RCMI Center for Cancer and Health Disparities Research | 007 | 17 | NIH | 4/1/2024 | $4,318,289 |
| | 2024 | 2024 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | U54MD007595 | RCMI Center for Cancer and Health Disparities Research | 008 | 17 | NIH | 5/29/2024 | $479,811 |
| | 2024 | 2024 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | OT2OD038383 | Xavier University of Louisiana Reaches the Underrepresented in Biomedical Research (XULA RUBR) | 000 | 1 | NIH | 8/27/2024 | $246,000 |
| | 2024 | 2024 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | R16NS141736 | Examining the Role of Allostatic Load and Neighborhood Disadvantage in Cognitive Function Trajectories among Midlife and Older Black Americans | 000 | 1 | NIH | 9/17/2024 | $187,500 |
| | 2024 | 2024 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | SC3GM142001 | Formulation of a targeted nanoparticle system for the treatment of chemoresistant breast cancer | 000 | 4 | NIH | 6/26/2024 | $112,500 |
| | 2024 | 2024 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | D3400006 | CENTERS OF EXCELLENCE (HBCU) | 01 | 37 | HRSA | 7/26/2024 | $0 |
| | 2024 | 2024 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | R16GM149412 | Inhibitors of Human Factor XIIIa as New Anticoagulants | 001 | 2 | NIH | 7/15/2024 | $14,959 |
| | 2024 | 2023 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | RL5GM118966 | BUILD at Xavier, Project Pathways II | 001 | 10 | NIH | 4/8/2024 | $42,293 |
| | 2024 | 2023 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | RL5GM118966 | BUILD at Xavier, Project Pathways II | 000 | 10 | NIH | 4/3/2024 | -$1 |
| | 2024 | 2023 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | TL4GM118968 | BUILD at Xavier, Project Pathways II | 001 | 10 | NIH | 4/4/2024 | -$42,293 |
| | 2024 | 2023 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | TL4GM118968 | BUILD at Xavier, Project Pathways II | 000 | 10 | NIH | 4/3/2024 | $0 |
| | 2024 | 2023 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1098 | ORLEANS | USA | U54MD007595 | RCMI Center for Cancer and Health Disparities Research | 000 | 16 | NIH | 10/26/2023 | $0 |
| | 2024 | 2023 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | UL1GM118967 | BUILD at Xavier, Project Pathways II | 000 | 10 | NIH | 4/4/2024 | $0 |
| | 2024 | 2023 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | U54MD007595 | RCMI Center for Cancer and Health Disparities Research | 003 | 15 | NIH | 3/27/2024 | -$2,841,178 |
| | 2024 | 2023 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | U54MD007595 | RCMI Center for Cancer and Health Disparities Research | 005 | 15 | NIH | 3/27/2024 | -$374,990 |
| | 2024 | 2023 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | U54MD007595 | RCMI Center for Cancer and Health Disparities Research | 006 | 16 | NIH | 3/27/2024 | $675 |
| | 2024 | 2023 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | U54MD007595 | RCMI Center for Cancer and Health Disparities Research | 006 | 16 | NIH | 3/27/2024 | $2,871,253 |
| | 2024 | 2023 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | U54MD007595 | RCMI Center for Cancer and Health Disparities Research | 006 | 16 | NIH | 3/27/2024 | $374,990 |
| | 2024 | 2023 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | U54MD007595 | RCMI Center for Cancer and Health Disparities Research | 006 | 16 | NIH | 3/27/2024 | $1,789 |
| | 2024 | 2022 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | U54MD007595 | RCMI Center for Cancer and Health Disparities Research | 004 | 14 | NIH | 3/27/2024 | -$1,789 |
| | 2024 | 2022 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | U54MD007595 | RCMI Center for Cancer and Health Disparities Research | 002 | 14 | NIH | 3/27/2024 | -$3,358 |
| | 2024 | 2022 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | U54MD007595 | RCMI Center for Cancer and Health Disparities Research | 001 | 14 | NIH | 3/27/2024 | -$26,717 |
| | 2024 | 2022 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | U54MD007595 | RCMI Center for Cancer and Health Disparities Research | 001 | 14 | NIH | 3/27/2024 | -$675 |
| | 2024 | 2022 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | SC3GM131986 | Inhibitors of the Intrinsic Pathway of Coagulation as New Anticoagulants | 001 | 4 | NIH | 1/10/2024 | -$106,500 |
| | 2024 | 2022 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1098 | ORLEANS | USA | D3400006 | CENTERS OF EXCELLENCE (HBCU) | 01 | 35 | HRSA | 4/18/2024 | -$49,623 |
| | 2024 | 2022 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | SC3GM127173 | The Impact of Patterned Feeding of a Palatable Diet on Excessive Alcohol Drinking | 001 | 4 | NIH | 8/20/2024 | $0 |
| | 2024 | 2022 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | SC2GM136557 | Exploring the protein structural features which regulate myoglobin's proton transfer dependent high-valent auto-reduction | 000 | 3 | NIH | 5/14/2024 | -$4,357 |
| | 2024 | 2022 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | SC3GM127173 | The Impact of Patterned Feeding of a Palatable Diet on Excessive Alcohol Drinking | 000 | 4 | NIH | 2/20/2024 | $0 |
| | 2024 | 2021 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | SC3GM131986 | Inhibitors of the Intrinsic Pathway of Coagulation as New Anticoagulants | 000 | 3 | NIH | 1/10/2024 | -$8,104 |
| | 2024 | 2020 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | SC3GM102050 | Formulation of Fenretinide Nanoparticles for Enhanced Bioavailability | 000 | 7 | NIH | 5/15/2024 | -$925 |
| | 2024 | 2019 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | R15CA242991 | Ceramides for Breast Cancer Treatment | 000 | 1 | NIH | 1/10/2024 | -$8,812 |
| | 2024 | 2018 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1056 | ORLEANS | USA | R15GM129682 | Factors contributing to the specificity of lysine deacetylases | 000 | 1 | NIH | 10/1/2023 | -$27,282 |
|
| Issue Date FY: 2023 ( Subtotal = $15,373,754 ) (Continued on the next page) |
| | 2023 | 2023 | XAVIER UNIVERSITY OF LOUISIANA | 1 DREXEL DR | NEW ORLEANS | LA | 70125-1098 | ORLEANS | USA | R16GM145484 | Role of the transcriptional corepressor TLE1 in the lung adenocarcinoma aggressiveness and progression | 000 | 2 | NIH | 5/1/2023 | $143,934 |
|
